Home-AMA: Healthcare 2026: [INTERVIEW] The Truth About Bioprinted Organ Liability

3D printing in healthcare is advancing faster than the legal frameworks built to govern it, and the gap is wider than most people realize.

Dr. Modupe B. Adewale has spent her PhD atRMIT University’sCollege of Business and Lawthinking about a question that most legal scholars have not yet got around to: when a hospital prints a human organ and it goes wrong, what does the law actually do?

Her research spans product liability, intellectual property, and bioethics. Dr. Adewale tells me that the frameworks governing each area were built for a world that bioprinting is already making obsolete, requiring her to build a new normative framework from scratch.

She calls it Moralist Bio-Utilitarianism, because neither pure utilitarian reasoning nor rights-based bioethics could hold the problem alone. “Pure utilitarian approaches can be very permissive,” she says. “They can justify strong forms of commodification or prioritize aggregate benefit in ways that underplay concerns about exploitation or unequal access.”

Deontological frameworks struggled with innovation. Bioprinting needed something that could assess outcomes in a consequentialist way while maintaining what she calls “a morally bounded space that prevents certain kinds of harm or unfairness from being justified purely on efficiency grounds.”

Wish to know more medical insights? Register now for ourAMA: Healthcare 2026 online conference!

The Murky Reality of Point-of-Care Liability

The liability question is the one courts will have to answer first, and the existing framework gives them very little to work with. Product liability law draws a firm line between manufacturers, who face strict liability, and clinicians, who are held to a negligence standard. That distinction has held up reasonably well for decades.

A hospital that uses a faulty hip implant is not the same legal actor as the company that made it. But “when a hospital designs, fabricates, and implants a bioprinted organ in-house,” Dr. Adewale says, “it is no longer merely using a product; it is actively creating it. In that sense, it begins to resemble a manufacturer and not just a mere incidental user.”

Source: 3D Printing Industry